Overview of Vietnam Pharmaceutical and Healthcare Report Q4 2017 – Includes 10-year forecasts to 2026
1. BMI View
3. Industry Forecast
4. Pharmaceuticals & Healthcare Risk/Reward Index
5. Regulatory Review
6. Market Overview
7. Competitive Landscape
8. Company Profile
9. Demographic Forecast
■ Ongoing regulatory reform and the relaxation of the 49% cap on foreign ownership will continue to increase the appeal of Vietnamese pharmaceutical equities to foreign investors.
■ The Association of Southeast Asian Nations harmonisation initiative, including the adoption of Western regulatory standards such as International Conference on Harmonisation and WHO guidelines.
■ Introduction of five-year exclusivity for clinical dossier data encouraging research-based multinationals.
■ If investment can be found for technological improvements, then there is great potential in the traditional Chinese medicine market, as well as Vietnam’s fledging biotechnology industry.
■ Full WTO membership improving the trading climate and potentially, in the longer term, redressing pharmaceutical trade issues.
■ Requirement for domestic companies to comply with international good
manufacturing practices should boost exports.
■ Increasing burden of chronic diseases to provide ample longer-term opportunities for prescription products
■ Government resistance to aligning patent law fully with international standards deterring multinational sector expansion.
■ Need to resolve infrastructural and power supply issues, as well as higher education
provision, before higher levels of foreign direct investment
To get this report for free, email us at Info.firstname.lastname@example.org